Dimension Therapeutics, Inc. (NASDAQ:DMTX) has been assigned a consensus recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $3.73.

DMTX has been the topic of a number of recent analyst reports. Canaccord Genuity lowered their price target on shares of Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, June 28th. Cantor Fitzgerald set a $3.00 price target on shares of Dimension Therapeutics and gave the stock a “hold” rating in a report on Saturday, June 10th. Chardan Capital reissued a “hold” rating on shares of Dimension Therapeutics in a report on Monday, August 14th. Finally, Zacks Investment Research downgraded shares of Dimension Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 10th.

A number of institutional investors and hedge funds have recently bought and sold shares of DMTX. Two Sigma Securities LLC purchased a new position in Dimension Therapeutics during the first quarter valued at $108,000. Goldman Sachs Group Inc. lifted its holdings in Dimension Therapeutics by 206.7% during the second quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 54,231 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC lifted its holdings in Dimension Therapeutics by 6.7% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 390,403 shares of the biotechnology company’s stock valued at $683,000 after purchasing an additional 24,489 shares in the last quarter. 70.75% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/16/dimension-therapeutics-inc-dmtx-given-consensus-recommendation-of-hold-by-analysts.html.

Dimension Therapeutics (DMTX) opened at 4.20 on Friday. The stock’s market cap is $105.22 million. Dimension Therapeutics has a 1-year low of $1.05 and a 1-year high of $9.98. The company’s 50 day moving average is $2.29 and its 200-day moving average is $1.67.

Dimension Therapeutics (NASDAQ:DMTX) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.49). Dimension Therapeutics had a negative net margin of 358.21% and a negative return on equity of 98.72%. The firm had revenue of $4.37 million for the quarter. Equities research analysts forecast that Dimension Therapeutics will post ($2.10) earnings per share for the current fiscal year.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Analyst Recommendations for Dimension Therapeutics (NASDAQ:DMTX)

Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.